Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Astronomers spot white dwarf star creating a colorful shockwave - 2Director Emerald Fennell explains why "Wuthering Heights" has quotation marks around the title
- 3This Week In Space podcast: Episode 192 — Space, 2026!
- 4Earth’s magnetic field protects life on Earth from radiation, but it can move, and the magnetic poles can even flip
- 5Australia Cracks Down on Gambling Ads as Prediction Markets Like Polymarket Remain Blocked
- Blue Origin launches New Glenn rocket on company's first NASA-scale science mission
- Israel, Gulf states report fresh missile and drone attacks
- Newly Built Sichuan Hydropower Bridge Collapses Into River Months After Opening
- Survey: Protected And Versatile Men's Razor
- Portugal among EU countries with the most people working close to 50 hours a week
- Deadly heat worldwide prompts $300 million for climate health research at COP30
- Swap The Amalfi Coast For This Low-Cost Ligurian Seaside Town
- Find the Standards of Viable Refereeing: Settling Debates with Strategy
- NASA's giant moon rocket, in photos
